NCT00979953View on ClinicalTrials.gov

Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee

PHASE2CompletedINTERVENTIONAL
Enrollment

408

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

June 30, 2010

Conditions
Osteoarthritis of the Knee
Interventions
DRUG

ADL5859

DRUG

ADL5747

DRUG

Oxycodone CR

DRUG

Placebo

Trial Locations (11)

28144

Cresent Medical Research, Salisbury

28401

New Hanover Medical Research, Wilmington

29621

Radient Research, Anderson

30281

Atlanta Knee and Shoulder Clinic, PC, Stockbridge

32117

Covance CRU, Inc, Daytona Beach

43213

Columbus Clinical Research, Columbus

43338

PSB Research, Mount Gilead

43623

Bone Joint & Spine Surgeons, Inc, Toledo

60031

Clinical Investigation Specialists, Inc, Gurnee

60612

University Rheumatoloty Center for Clinical Research, Chicago

78209

Quality Research, San Antonio

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT00979953 - Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee | Biotech Hunter | Biotech Hunter